Newsroom

롯데바이오로직스의
최신 소식을 전해드립니다.

Key visual

SNS 2025년 12월 19일

🏭 Facility Friday | Dual-Site Overview

No alternative text description for this image

 

🏭 Facility Friday | Dual-Site Overview

🌐 LOTTE Biologics delivers integrated biologics and bioconjugate manufacturing across the full product lifecycle.

🔗 Through our unified Dual Hub Service model in the United States and South Korea, we strengthen supply security, enable scalable manufacturing pathways, and uphold aligned quality standards across regions.

🧬 Our capabilities include phase-appropriate drug substance manufacturing for mammalian-cell-based biologics—such as monoclonal antibodies, fusion proteins, and multispecific modalities—along with fully integrated Antibody-Drug Conjugate (ADC) manufacturing supported by onsite conjugation facilities.

📍Join us each week as Facility Fridays highlights our sites, technologies, and the capabilities that power our work.
If you’re looking for a partner to support your biologics or ADC programs, let's discuss how our dual-site platform can help.